In this 15-minute accredited CME audiocast, Dr. Tsao presents 2 cases of patients with advanced NSCLC without a driver mutation and discusses how to manage these patients after first-line treatment. The first case is a patient who progresses on platinum-based chemotherapy, and the second case is a patient who progresses on pembrolizumab-pemetrexed-carboplatin.
- Host: Anne S. Tsao, MD
Available credits: 0.25
Anne S. Tsao, MD
Professor, Department of Thoracic/Head and Neck Medical Oncology
Division of Cancer Medicine
Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
University of Texas MD Anderson Cancer Center
Christie Avraamides, PhD
Clinical Content Manager
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
East Lansing, MI
Upon completion, participants should be able to:
- Develop individualized treatment plans for patients with metastatic NSCLC without driver mutations in the second-line setting
This activity is intended for oncologists.
The availability of new first-line treatment options for metastatic non–small cell lung cancer (NSCLC) in patients without an actionable mutation allows for greater treatment individualization and improved outcomes. However, oncologists are now challenged to optimally sequence therapies in the second-line setting because there are no randomized trials to guide therapeutic decisions. Furthermore, evidence suggests that the selection of second-line agents in metastatic NSCLC without an actionable mutation may not be consistent with guideline recommendations. Therefore, oncologists need education and guidance on the factors that influence therapeutic sequencing and on second-line treatment options.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
To receive credit, read the introductory CME material, listen to the audiocast, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Anne S. Tsao, MD
Consulting fees/advisory boards: AstraZeneca, Boehringer-Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Eli Lilly and Company, EMD Serono, Inc., F. Hoffman-La Roche Ltd., Genentech, Huron, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Seattle Genetics, Takeda Pharmaceuticals North America, Inc.
Contracted research: Boehringer-Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Eli Lilly and Company, Epizyme, Genentech, Merck & Co., Inc., Millennium: The Takeda Oncology Company, Polaris Pharmaceuticals, Seattle Genetics
The peer reviewers and activity planners have no financial relationships to disclose.
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
© 2019 Med-IQ, Inc.
Bradley J. Monk, MD, FACS, FACOGPeer